Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Complement receptor 1 (CR1) expression in chronic myeloid leukemia.

F Lanza1, G Castoldi

  • 1Institute of Hematology, University of Ferrara, Italy.

Leukemia & Lymphoma
|September 1, 1992
PubMed
Summary

Complement receptor 1 (CR1) deficiency on neutrophils is linked to chronic myeloid leukemia (CML) progression and reduced tumor cell cytotoxicity. Recombinant alpha interferon therapy may restore CR1 levels in CML patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Description of 18 PNH patients with prevalent GPI-deficient monocytes. An Italian survey.

British journal of haematology·2025
Same author

Overview on novel strategies and current guidelines for hematopoietic stem cell mobilisation and collection.

Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis·2023
Same author

[Cultured platelets].

Bulletin de l'Academie nationale de medecine·2020
Same author

Head down tilt 15° in experimental intracerebral hemorrhage: a randomized noninferiority safety trial.

European journal of neurology·2020
Same author

Convalescent plasma, an apheresis research project targeting and motivating the fully recovered COVID 19 patients: A rousing message of clinical benefit to both donors and recipients alike.

Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis·2020
Same author

WITHDRAWN: Convalescent plasma, an apheresis research project targeting and motivating the fully recovered COVID 19 patients: A rousing message of clinical benefit to both donors and recipients alike.

Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis·2020

Area of Science:

  • Immunology
  • Hematology
  • Oncology

Background:

  • Complement receptor 1 (CR1), also known as CD35, is a glycoprotein crucial for neutrophil functions like phagocytosis and potential tumor cell cytotoxicity.
  • The specific role of CR1 in chronic myeloid leukemia (CML) remains incompletely understood.
  • CML often presents with significantly reduced CR1 antigen expression on neutrophils and myeloid precursors, correlating with disease activity and advanced stages.

Purpose of the Study:

  • To investigate the role of CR1 in chronic myeloid leukemia (CML).
  • To explore the relationship between CR1 expression levels, disease progression, and neutrophil function in CML.
  • To assess the impact of CR1 deficiency on tumor cell cytotoxicity in CML patients.

Main Methods:

  • Analysis of CR1 antigen expression on neutrophils and myeloid precursors in CML patients at various disease stages.

Related Experiment Videos

  • Assessment of neutrophil response to PMA stimulation in CR1-deficient CML neutrophils.
  • Evaluation of CR1 levels following treatment with recombinant alpha interferon in CML patients.
  • Investigation of neutrophil-mediated tumor cell lysis using anti-CR1 monoclonal antibodies in normal and CML individuals.

    • Main Results:

    • Reduced CR1 expression in CML correlates with disease activity, advanced stages, and blastic crisis.
    • Low CR1 expression at disease onset is associated with an increased risk of blastic transformation.
    • CR1-deficient CML neutrophils exhibit impaired response to PMA stimulation, suggesting defective granular storage.
    • Recombinant alpha interferon therapy normalized CR1 receptor levels in CR1-deficient CML patients.
    • CR1 neutralization by monoclonal antibodies suppressed tumor cell lysis in both normal and CML individuals, indicating CR1's role in this function.

    Conclusions:

    • CR1 plays a significant role in neutrophil function and immune response within the context of CML.
    • CR1 deficiency is a marker of disease severity and potentially predicts blastic transformation in CML.
    • CR1 is implicated in neutrophil-mediated tumor cell cytotoxicity, and its levels are directly related to this lytic activity in CML patients.